Warfarin vs Dabigatran for elective direct current cardioversion (DCCV)

In clinical practice, achieving 4 weeks of therapeutic anticoagulation with warfarin is challenging and hinders timely DCCV. Dabigatran is a safe and effective alternative. We evaluated the difference in time to DCCV and success rate between those on dabigatran compared to warfarin.

A. Kueh, D. Judson, K. Reed, R. Gabriel, J. Looi, D. Heaven, N. van Pelt
Counties Manukau District Health, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Resource Library Item

This resource is available for registered members of CSANZ.

Click the button below to log in to HeartOne and access this resource. Please note that CPD credit is NOT automatically assigned for accessing resources directly.

Go to resource

Tags: , , , , , , , , , ,

Interested in joining CSANZ?